Glycan Therapeutics, LLC is an emerging company specializing in glycomics, the synthesis of heparin and chondroitin sulfates for medical uses. The companys proprietary enzyme-based technology enables high efficiency synthesis of these sulfated carbohydrates. Glycomics offers exciting potential as a source of new therapeutics, but has been limited by the lack of a large scale, cost effective synthesis platform to deliver pure oligosaccharides at commercial vollumes. Glycans is focused on development of heparin like glycans, either in-house, or in cooperation with other companies, into novel therapies. Glycans lead compound is a heparin like 12-mer designed to replace animal-sourced heparin anticoagulants. Pre-clinical testing has been performed in mouse, rat and primate models, to confirm the compounds anticoagulant activity and reversibility by protamine. Preliminary toxicity studies in rats and dogs demonstrate that the 12-mer is safe.
